共 12 条
[1]
Lipid-lowering therapy and stabilization of atherosclerotic plaques. Krone W,Muller WD. Thrombosis and Haemostasis . 1999
[2]
Lipid-lowering therapy in acute coronary syndromes. Sacks FM. The Journal of The American Medical Association . 2001
[3]
cholesterol reduction rapidly improves endothelial function after acute coronary syndromes.The RECIFE trial. Dupuis J,Tardif JC,Cernacek P,et al. Circulation . 1999
[4]
Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE trial. Dupuis J,Tardif JC,Cernack P,et al. Circulation . 1999
[5]
For the Cholesterol and Recurrent Event ( CARE) investigators.Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Flaker GC,Warnica JW,Sacks FM,et al. Journal of the American College of Cardiology . 1999
[6]
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Pederson JR,Olsson AG,Faergeman V,et al. Circulation . 1998
[7]
Effects of lipid-lowering by simvastatin on human ahterosclerotic lesions. Corti R,Fayad ZA,Fuster V,et al. Circulation . 2001
[8]
Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. Williams JK,Sukhova GK,Herrington DM,et al. Journal of the American College of Cardiology . 1998
[9]
Pravastatin treament increases collagen content and decreases lipid content, inflammation,metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Crisby M,Nordin FG,Shah PK,et al. Circulation . 2001